Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Hyperglycemia Drug Induced
Interventions: BIOLOGICAL: REMD-477
Sponsor: Duke University